AWH News and Press, Aspira Women's Health Inc. From 07/08/21

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) today announced its OVA1 ® risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health’s Clinical Appr...

AUSTIN, Texas, June 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease, released the analytical and initial clinical data for OVASight™ in an abstract titled ȁ...

RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Summer Solstice - Best Ideas fro...

AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for ...

Image source: The Motley Fool. Aspira Women's Health Inc. (NASDAQ: AWH) Q1 2021 Earnings Call May 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Aspira Women's Health Inc. (AWH) Q1 2021 Earnings Call Transcript...

Aspira Women's Health Inc. (AWH) Q1 2021 Results Conference Call May 13, 2021 04:30 PM ET Company Participants Valerie Palmieri - President and CEO Bob Beechey - CFO Kaile Zagger - COO Dr. Lesley Northrop - Chief Scientific Officer Dr. Elena Ratner - Global Chief Medical Advisor and Clinical ...

Aspira Women’s Health (AWH): Q1 GAAP EPS of -$0.05 beats by $0.12.Revenue of $1.49M (+22.1% Y/Y) beats by $0.12M.Press Release For further details see: Aspira Women’s Health EPS beats by $0.12, beats on revenue

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended, March 31, 2021. ...

-   Analytical and Initial Clinical Validation performance for Aspira’s OVASight™ blood-based biomarker test for Ovarian Malignancy risk assessment in women with Adnexal Masses. -   Data demonstrates the ability to identify Ovarian Cancer Risk i...

AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest privat...